Zacks Investment Research
25 May 2026, 14:46 UTC · 25w ago
ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand
Impact · against what's priced in
ImmuCell Corporation's Q1 results show strong growth in U.S. sales and margin expansion, providing a fundamental catalyst for the stock. While international sales are declining, the dominant performance in the U.S. scours biologics market drives overall profitability.
- ICCC+0.60
No priced-in read yet





